Jemperli was approved for similar expanded use in endometrial cancer in the United States in August 2024. The drug is also approved for second-line endometrial cancer and dMMR recurrent or ...

GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemo ... Subscribe now to see this Premium News article from Alliance News ...

The tolerability and safety profile for Jemperli combined with carboplatin-paclitaxel was consistent with the known safety profiles of the individual agents. Endometrial cancer originates in the ...

UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its pipeline ahead of a key patent expiry, as US hedge fund Citadel took the largest short position ...

Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for the first time, after NICE backed use of GlaxoSmithKline's PD-1 inhibitor Jemperli via the ...

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

approval of GSK's Jemperli, combined with chemotherapy for the treatment of advanced or recurrent endometrial cancer. "GSK and University of Oxford partner for cancer vaccine research" was ...

Jemperli (Dostarlimab): GlaxoSmithKline Jemperli (dostarlimab) is an anti-PD-1 monoclonal antibody developed by GlaxoSmithKline that has been approved for use in advanced or recurrent endometrial ...

GSK's Jemperli has also received expanded approval from the European Commission for certain endometrial cancer cases. In acquisition news, GSK plans to acquire Boston-based biopharmaceutical firm ...